BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

743 related articles for article (PubMed ID: 19190818)

  • 1. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Platelets; 2011; 22(3):188-95. PubMed ID: 21231857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry.
    von Beckerath N; Sibbing D; Jawansky S; Braun S; Morath T; Vogt W; Schömig A; Kastrati A
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):46-52. PubMed ID: 19823079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
    Bal Dit Sollier C; Berge N; Boval B; Dubar M; Drouet L
    Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Heart; 2010 Feb; 96(3):186-9. PubMed ID: 19687016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to antiplatelet therapy is independent of endogenous thrombin generation potential.
    Gremmel T; Panzer S; Steiner S; Seidinger D; Koppensteiner R; Pabinger I; Kopp CW; Ay C
    Thromb Res; 2013 Jul; 132(1):e24-30. PubMed ID: 23623170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.
    Aradi D; Magyarlaki T; Tokés-Füzesi M; Rideg O; Vorobcsuk A; Komócsi A
    Platelets; 2010; 21(7):563-70. PubMed ID: 20642320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation.
    Siller-Matula JM; Haberl K; Prillinger K; Panzer S; Lang I; Jilma B
    Thromb Res; 2009 Apr; 123(6):874-80. PubMed ID: 19135705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
    Cuisset T; Frere C; Quilici J; Gaborit B; Castelli C; Poyet R; Bali L; Morange PE; Alessi MC; Bonnet JL
    Am J Cardiol; 2009 Oct; 104(8):1078-82. PubMed ID: 19801028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel?
    Gremmel T; Calatzis A; Steiner S; Kaider A; Seidinger D; Koppensteiner R; Kopp CW; Panzer S
    Platelets; 2010; 21(7):515-21. PubMed ID: 20624009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting.
    Marcucci R; Gori AM; Paniccia R; Giusti B; Valente S; Giglioli C; Buonamici P; Antoniucci D; Abbate R; Gensini GF
    Thromb Haemost; 2010 Aug; 104(2):279-86. PubMed ID: 20508896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients.
    Paniccia R; Antonucci E; Maggini N; Miranda M; Gori AM; Marcucci R; Giusti B; Balzi D; Prisco D; Abbate R
    Thromb Haemost; 2010 Aug; 104(2):287-92. PubMed ID: 20458439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
    Pampuch A; Cerletti C; de Gaetano G
    Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists'-inducible platelet reactivity.
    Gremmel T; Kopp CW; Seidinger D; Giurgea GA; Koppensteiner R; Steiner S; Panzer S
    Atherosclerosis; 2009 Dec; 207(2):608-13. PubMed ID: 19616779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    J Cardiovasc Pharmacol; 2010 Nov; 56(5):532-9. PubMed ID: 20729752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment.
    Sibbing D; Braun S; Jawansky S; Vogt W; Mehilli J; Schömig A; Kastrati A; von Beckerath N
    Thromb Haemost; 2008 Jan; 99(1):121-6. PubMed ID: 18217143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
    Neubauer H; Lask S; Engelhardt A; Mügge A
    Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation.
    Bidet A; Jais C; Puymirat E; Coste P; Nurden A; Jakubowski J; Nurden P
    Platelets; 2010; 21(2):94-100. PubMed ID: 20148735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.